-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Mydecine Innovations Group Reports Q2 Financial Results And Management Updates
Mydecine Innovations Group Reports Q2 Financial Results And Management Updates
After the resignation of several key board members on August 12, Mydecine Innovations Group (OTC:MYCOF) reported its financial results.
For the period corresponding to the six months ended June 30, 2022:
-
Total cash was $324,146
-
Net loss due to common stockholders was $8.09 million from operations, or a basic and diluted loss per share of $(1.31), compared to net loss from operations of $13.53 million, or a basic and diluted loss per share of ($3.04) for the same period of 2021.
-
R&D expenses for the six-month period totaled $1,702,011, compared to $1,322,130 for the same period in 2021.
-
R&D expenses for the three-month period totaled $652,486, compared to $1,091,920 for the same period in 2021.
In relation to the last category of expenses, Mydecine announced the start of a government-funded trial testing its proprietary, FDA-approved psilocybin-based MYCO-001 for tobacco addiction in June. In July, the company filed a patent application for MYCO-006, their family of novel short-acting MDMA analogs.
The apparently sudden resignation of the company's designated directors Damon Michaels, Josephine Wu, Dr. Saeid Babaei and Dr. Victoria Hale was announced on Friday, together with the launch of a search for candidates with knowledge of drug development to fill two board positions, as Michaels will remain as the company's COO.
The three remaining board members are Josh Bartch, Rob Roscow and Todd Heinzl.
According to Mydecine's statements, "The departures are part of a larger organizational shift that will allow the corporation to concentrate on its core competencies with more efficiency."
Photo by Sean Pollock on Unsplash
After the resignation of several key board members on August 12, Mydecine Innovations Group (OTC:MYCOF) reported its financial results.
後幾名主要董事會成員辭職8月12日,Mydecine創新集團(場外交易代碼:MYCOF)報告了其財務業績。
For the period corresponding to the six months ended June 30, 2022:
截至2022年6月30日止六個月的期間:
-
Total cash was $324,146
-
Net loss due to common stockholders was $8.09 million from operations, or a basic and diluted loss per share of $(1.31), compared to net loss from operations of $13.53 million, or a basic and diluted loss per share of ($3.04) for the same period of 2021.
-
R&D expenses for the six-month period totaled $1,702,011, compared to $1,322,130 for the same period in 2021.
-
R&D expenses for the three-month period totaled $652,486, compared to $1,091,920 for the same period in 2021.
-
現金總額是324,146美元
-
淨虧損由於普通股股東的虧損為809萬美元,或每股基本和稀釋後虧損1.31美元,而2021年同期運營淨虧損1353萬美元,或每股基本和稀釋後虧損3.04美元。
-
研發費用這六個月的收入總額為1 702 011美元,而2021年同期為1 322 130美元。
-
研發費用這三個月的收入總額為652,486美元,而2021年同期為1,091,920美元。
In relation to the last category of expenses, Mydecine announced the start of a government-funded trial testing its proprietary, FDA-approved psilocybin-based MYCO-001 for tobacco addiction in June. In July, the company filed a patent application for MYCO-006, their family of novel short-acting MDMA analogs.
關於最後一類費用,Mydecine宣佈在6月份開始一項由政府資助的試驗,測試其專有的、FDA批准的基於裸蓋菇素的myco-001治療煙草成癮。今年7月,該公司為他們的新型短效MDMA類似物Myco-006申請了專利。
The apparently sudden resignation of the company's designated directors Damon Michaels, Josephine Wu, Dr. Saeid Babaei and Dr. Victoria Hale was announced on Friday, together with the launch of a search for candidates with knowledge of drug development to fill two board positions, as Michaels will remain as the company's COO.
這個公司指定董事顯然突然辭職達蒙·邁克爾斯、約瑟芬·吳、賽義德·巴巴伊博士和維多利亞·黑爾博士於週五宣佈,同時開始尋找具有藥物開發知識的候選人來填補兩個董事會職位,邁克爾斯將繼續擔任公司的首席運營官。
The three remaining board members are Josh Bartch, Rob Roscow and Todd Heinzl.
剩下的三名董事會成員是喬什·巴奇、羅布·羅斯考和託德·海因茨爾。
According to Mydecine's statements, "The departures are part of a larger organizational shift that will allow the corporation to concentrate on its core competencies with more efficiency."
根據Mydecine的陳述,這些離職是更大的組織轉變的一部分,這將使公司能夠更有效地專注於其核心能力。“
Photo by Sean Pollock on Unsplash
肖恩·波洛克在Unspash上的照片
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧